This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zabofloxacin

Dong Wha Pharmaceutical Ind. Co.

Drug Names(s): DW224a, PB-101, ZFXA

Description: Zabofloxacin is a fluoroquinolone antimicrobial agent with enhanced in-vitro activity against Streptococcus pneumoniae, including strains resistant to other antibiotics.

Deal Structure: Pacific Beach and Dong Wha
In August 2007, Pacific Beach BioSciences and Dong Wha announced an agreement granting PB BioSciences exclusive rights to develop and commercialize Zabofloxacin (PB-101, DW-224a).

Under the terms of the agreement, Dong Wha granted PB BioSciences exclusive development and marketing rights worldwide, except in Japan, Korea, China, Taiwan, Singapore, Indonesia, India, Thailand, Malaysia, Vietnam, Hong Kong, Australia, and New Zealand. In return, PB BioSciences will make a one-time up-front payment on the execution of the license followed by potential milestone payments of up to USD $56.5 million if Zabofloxacin is successfully developed and commercialized. In addition, Dong Wha will receive royalties on worldwide sales of Zabofloxacin.

In April 2010, Pacific Beach BioSciences changed its name to IASO Pharma Inc.

As of May 2012, it appears that IASO Pharma has gone out of business.


Zabofloxacin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug